Navigation Links
ULURU Inc. Reports Second Quarter 2008 Financial Results

ADDISON, Texas, Aug. 11 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today reported financial results for the second quarter ended June 30, 2008.

For the quarter ended June 30, 2008, the net loss attributable to common stockholders was $2,334,000, or $0.04 per share, compared to a net loss of $1,209,000, or $0.02 per share, for the corresponding period in 2007. The second quarter 2008 net loss was impacted by non-cash expenses of $560,000, which included share-based compensation, amortization, and depreciation of $261,000, $269,000 and $30,000, respectively, whereas the second quarter 2007 net loss included non-cash expenses of $405,000, which included share-based compensation, amortization, and depreciation of $119,000, $269,000 and $17,000, respectively.

Income Statement

Revenues for the second quarter of 2008 were $96,000, compared with $119,000 for the same period last year. The decrease of $23,000 in revenues is primarily attributable to a decrease in sponsored research of $35,000, as the prior year revenue was non-recurring.

Total costs and expenses, including amortization and depreciation, increased by $975,000 in the second quarter of 2008 to $2,508,000, as compared with the corresponding period in 2007 where total costs and expenses, including amortization and depreciation, were $1,533,000. The overall expense increase is primarily attributable to increases in Research and Development of $314,000 and increases in Selling, General and Administrative of $648,000. The increase in Research and Development expenses is attributed to additional costs in direct research for Altrazeal(TM) related products of $35,000 and OraDisc(TM) related products of $16,000, increases for our clinical testing programs of $53,000, regulatory consulting and expenses of $66,000, and additional scientific personnel costs, including share-based compensation, of approximately $145,000. The Selling, General and Administrative expense increase was comprised of administrative personnel costs of $299,000, which is inclusive of $134,000 of share-based compensation, along with increased expenses of $323,000 associated with the ramp-up of our initial sales and marketing efforts for our wound care product line.

Interest and miscellaneous income decreased in the second quarter of 2008 to $79,000 as compared with $206,000 for the same period in the previous year. The decrease of $127,000 is attributable to a decrease in interest income due to lower cash balances and lower interest yields in 2008 versus prior year.

Balance Sheet

Cash and cash equivalents totaled $11,684,000 at June 30, 2008, a decrease of $2,296,000 as compared to our cash and cash equivalents at December 31, 2007 of $13,980,000. The decrease in net cash for the six months ended June 30, 2008 was due primarily to the net cash used in operations of $1,781,000 and the expenditure of $420,000 for manufacturing equipment purchases associated with our OraDisc(TM) and Altrazeal(TM) products.


Commenting on the financial results Kerry P. Gray, President and CEO stated, "With the exception of a delayed receipt of a milestone payment associated with a regulatory filing, our operating results were in line with our forecast projections. The increase in operating expenses are primarily associated with the commercialization and development of our Altrazeal(TM) range of products. To support the launch of Altrazeal(TM), we will continue to invest in our sales and marketing efforts. These efforts are expected to establish key opinion leader support and to develop our business in burn and wound care centers."

During the second quarter we achieved numerous important milestones to include;
-- Launch of Altrazeal(TM);

-- Establishment of our commercial infrastructure, which now includes nine

product specialists;

-- Signing of definitive agreement to acquire Bio Med Sciences, Inc.; and

-- Signing of an additional OraDisc(TM) development agreement.

In conjunction with strategic partners, advancements for of the development of wound care actives in Altrazeal(TM) continues. Additionally, we have advanced the development of Altrazeal(TM) containing silver and anticipate filing a 510k regulatory application with the FDA within the next 60 days.

Gray continued, "We are very pleased with the reception Altrazeal(TM) has received both in burn units and wound care centers. The clinical experience to date is very positive, with the advantages of the Nanoflex technology being demonstrated in a wide variety of difficult to treat wounds. The pre-clinical results including, ease of application, use without a second dressing, accelerated healing, and reduced dressing changes have been demonstrated in numerous wound types. Importantly, patient feedback on the comfort of the dressing and pain has been very positive."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing our innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the expected launch of our wound dressing product, development of a silver containing product, impact on cost of the production scale-up, the launch of additional products, and our expectation that our licensing fees will increase and offset increased expenses. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology, pre-clinical results for our products and advantages of our products and the consummation of the proposed acquisition of Bio Med Sciences, Inc. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145





Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007


License fees $25,522 $16,831 $39,293 $154,880

Royalty income 84,772 81,456 160,346 136,918

Product sales 405 --- 166,878 ---

Other (15,000) 20,501 (15,000) 210,501

Total Revenues 95,699 118,788 351,517 502,299


Cost of goods sold 119 --- 137,734 ---

Research and

development 867,544 553,755 1,742,760 1,119,163

Selling, general and

administrative 1,341,235 693,588 2,234,470 1,288,826

Amortization 269,183 268,630 538,367 534,173

Depreciation 30,202 17,173 50,474 33,877

Total Costs and

Expenses 2,508,283 1,533,146 4,703,805 2,976,039

OPERATING (LOSS) (2,412,584) (1,414,358) (4,352,288) (2,473,740)

Other Income (Expense)

Interest and

miscellaneous income 78,888 205,825 203,933 419,630

Interest expense --- --- --- (1,574)


TAXES (2,333,696) (1,208,533) (4,148,355) (2,055,684)

Income taxes --- --- --- ---

NET (LOSS) $(2,333,696) $(1,208,533) $(4,148,355) $(2,055,684)

Basic and diluted net

(loss) per common

share $(0.04) $(0.02) $(0.07) $(0.03)



OUTSTANDING 62,466,881 61,916,935 62,445,519 61,326,745



June 30, 2008 December 31, 2007

(Unaudited) (Audited)

Cash and cash equivalents $11,684,039 $13,979,828

Current assets 12,536,715 15,536,146

Property and equipment, net 1,891,882 1,532,881

Other assets 10,664,330 11,053,976

Total assets 25,092,927 28,123,003

Current liabilities 1,432,315 1,389,989

Long term liabilities - deferred

revenue 1,055,777 495,281

Total liabilities 2,488,092 1,885,270

Total stockholders' equity 22,604,835 26,237,733

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ULURU Inc. to Present at the 8th World Biomaterials Congress
2. ULURU Inc. Announces Update on Recent Development
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... 2015 , ... Whitehouse Laboratories is pleased to announce that it has completed ... strictly dedicated to basic USP 61, USP 62 and USP 51 testing specific to ... chemistry and micro testing performed by one supplier. Management has formally announced ...
(Date:11/23/2015)... Ceres, Inc . (Nasdaq: CERE ), an agricultural ... year ended August 31, 2015 and provided an update ... --> During fiscal year 2015, Ceres refocused its ... better balance of yield, energy and nutrition. Among other ... crop input providers and made significant progress in advancing ...
(Date:11/23/2015)... , ... November 23, 2015 , ... Noblis, Inc., a ... former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined the Noblis ... an incredibly distinguished career in the intelligence community and the private sector,” said ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):